Pfizer and BioNTech have released some extraordinary findings from a Phase 3 trial involving 46,307 participants, between seven days and six months after a second dose was administered. The vaccine was found to have a 91.3 per cent efficacy rate. These findings line up with the real world data coming out of Israel, which has used the Pfizer vaccine to inoculate its population, and reported several weeks ago that it proved 94 per cent effective in preventing symptomatic illness.
But on top of the overall efficacy rate came even better news: Pfizer is reporting that the ‘vaccine was 100 per cent effective in preventing severe disease’ as defined by the US Centers for Disease Control. The 32 cases of severe disease were all found in the placebo group, while zero were found in the vaccinated group.
Comments
Join the debate for just $5 for 3 months
Be part of the conversation with other Spectator readers by getting your first three months for $5.
UNLOCK ACCESS Just $5 for 3 monthsAlready a subscriber? Log in